case_images: PMC11700920_01
case_images: Cutaneous adverse events (CAEs) during pembrolizumab combination chemotherapy against cervical cancer. Regimen overview. (a) Delayed CAEs after the first treatment course. (b-d) Case 1, (g and h) Case 2, (j and k) Case 3, (m and n) Case 4. Immediate CAEs during the second treatment course (e and f) Case 1, (i) Case 2, (l) Case 3.
case_images: JDE-52-132-g001.jpg
case_images: PMC11700920_04_JDE-52-132-g001.jpg
case_images: jde17521-fig-0001
case_images: Case 4 involved a 38-year-old woman with no history of prior treatment or allergy who presented with generalized EM and fever 7 days after the first course of paclitaxel + cisplatin + bevacizumab + PEM (Table 1, Figure 1m,n).
case_images: PMC11700920_02
case_images: Cutaneous adverse events (CAEs) during pembrolizumab combination chemotherapy against cervical cancer. Regimen overview. (a) Delayed CAEs after the first treatment course. (b-d) Case 1, (g and h) Case 2, (j and k) Case 3, (m and n) Case 4. Immediate CAEs during the second treatment course (e and f) Case 1, (i) Case 2, (l) Case 3.
case_images: JDE-52-132-g001.jpg
case_images: PMC11700920_04_JDE-52-132-g001.jpg
case_images: jde17521-fig-0001
case_images: Case 4 involved a 38-year-old woman with no history of prior treatment or allergy who presented with generalized EM and fever 7 days after the first course of paclitaxel + cisplatin + bevacizumab + PEM (Table 1, Figure 1m,n).
case_images: PMC11700920_03
case_images: Cutaneous adverse events (CAEs) during pembrolizumab combination chemotherapy against cervical cancer. Regimen overview. (a) Delayed CAEs after the first treatment course. (b-d) Case 1, (g and h) Case 2, (j and k) Case 3, (m and n) Case 4. Immediate CAEs during the second treatment course (e and f) Case 1, (i) Case 2, (l) Case 3.
case_images: JDE-52-132-g001.jpg
case_images: PMC11700920_04_JDE-52-132-g001.jpg
case_images: jde17521-fig-0001
case_images: Case 4 involved a 38-year-old woman with no history of prior treatment or allergy who presented with generalized EM and fever 7 days after the first course of paclitaxel + cisplatin + bevacizumab + PEM (Table 1, Figure 1m,n).
case_images: PMC11700920_04
case_images: Cutaneous adverse events (CAEs) during pembrolizumab combination chemotherapy against cervical cancer. Regimen overview. (a) Delayed CAEs after the first treatment course. (b-d) Case 1, (g and h) Case 2, (j and k) Case 3, (m and n) Case 4. Immediate CAEs during the second treatment course (e and f) Case 1, (i) Case 2, (l) Case 3.
case_images: JDE-52-132-g001.jpg
case_images: PMC11700920_04_JDE-52-132-g001.jpg
case_images: jde17521-fig-0001
case_images: Case 4 involved a 38-year-old woman with no history of prior treatment or allergy who presented with generalized EM and fever 7 days after the first course of paclitaxel + cisplatin + bevacizumab + PEM (Table 1, Figure 1m,n).